JACKSON CENTER, PA / ACCESSWIRE / July 22, 2020 / Halberd Corporation (OTC PINK:HALB) announced their Chief Technical Officer and Head of Scientific Advisory Board, Dr. Patricio Reyes presented A Community Information Session virtual event hosted yesterday by the Brain Injury Alliance of Arizona, on “Covid-19 & the Nervous System; Neurological Complications That Can Result”. Dr. Reyes has been requested to repeat this virtual event for the Arizona State Legislature at 2:30 PM (AZ Time) on Friday, July 24, 2020.
Dr. Reyes presented findings from several sources which indicate that Covid-19 can be accompanied by specific neurological symptoms, which can help in determining the direction and intensity of treatment of Covid-19.
Patricio Reyes, MD, FAAN, is a board certified neurologist and neuropathologist and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona. Dr. Reyes is the Chief Medical Officer and Board Member of the National Football League Retired Players Association.
Dr. Reyes established the first clinic dedicated to the treatment of Alzheimer’s disease and dementia at the Audie Murphy VA Hospital and at the University of Texas in San Antonio, where he pioneered the rapid brain autopsy system. He went on to build the same programs at Jefferson Medical College and Creighton University School of Medicine. He was principal investigator of the first FDA approved oral drug and skin patch treatment for Alzheimer’s disease and the recipient of several research grants from the VA, NIH, NIA, industry, public and private foundations and donations from grateful patients, along with several prestigious achievement awards.
William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, “Dr. Reyes is the principal force within Halberd Corporation to develop our treatment for patients suffering from Covid-19. The work he is doing with the Brain Injury Alliance of Arizona is very much in sync with his activities at Halberd.”
Halberd, Inc. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” It also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation